Research Article
Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance
Table 1
Patient and donor characteristics, and
antiviral therapy at the time the ISH biopsy in HCV ISH positive (group 1) and
negative (group 2) patients.
| Variables | Group 1 ISH positive
| Group 2 ISH negative
| |
| Patient age at LT | 49 ±
11 | 52 ±
11 | .66 | Female gender (patient) | 40% | 13% | .13 | Caucasian (patient) | 90% | 87% | .69 | Recipient body mass index | 31 ±
7 | 29 ±
6 | .51 | MELD at LT | 14 ±
5 | 18 ±
9 | .42 | Genotype 1 (unknown in 1 patient per group) | 56% | 86% | .11 | Donor age | 47 ±
13 | 43 ±
14 | .82 | Female gender (donor) | 40% | 53% | .51 | Caucasian (Donor) | 90% | 67% | .34 | Cold ischemia time, hours | 7 ±
2 | 7 ±
2 | .74 | Warm ischemia time, minutes | 39 ±
9 | 34 ±
10 | .28 | Tacrolimus as primary immune suppressant | 100% | 83% | .23 | Steroid bolus treated ACR | 30% | 40% | .61 | LT to ISH biopsy interval, months | 23 ±
10 | 24 ±
12 | .91 |
|
|